ReviewClinical epigenetics2026
Choline and DNA methylation: impact across metabolic, oncogenic and neurodevelopmental disorders.
Review in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prenatal Choline and Betaine Differentially Program Adult Hepatic One-Carbon Metabolism in Wistar Rats.Journal of agricultural and food chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundAberrant DNA methylation patterns are increasingly recognized as contributors to a wide range of conditions, including metabolic, oncogenic, and neurodevelopmental disorders. Nutritional factors, such as choline, can shape methylation potential via methyl group donation. The purpose of this narrative review is to synthesize current evidence on the DNA methylation landscapes underlying health and disease paradigms, with a focus on the role of choline as a compelling target for modulating epigenetic states. A comprehensive literature review search was conducted in PubMed to identify relevant studies, with additional articles retrieved from review papers. MAIN BODY: In models of metabolic-associated steatotic liver disease, choline deficiency yields perturbed methylation of genes involved in lipid metabolism and mitochondrial function, whereas supplementation restores methylation balance and improves metabolic outcomes. In hepatocellular carcinomas, choline modulates methylation of tumor suppressor genes and oncogenes, interacting with one-carbon metabolism enzymes and the Wnt/β-catenin pathway. During development, gestational choline supplementation induces long-lasting epigenetic changes across multiple systems, affecting genes involved in stress regulation, neurodevelopment, and metabolism. Postnatal choline supplementation can also induce epigenetic remodeling, mitigating established aberrant methylation patterns in adulthood. Across models, choline availability modulates the methylation status of key regulatory genes in a highly context-dependent manner, as it is capable of either increasing or decreasing DNA methylation depending on molecular targets, developmental stage, tissue type, and disease state in a sex-specific manner.
conclusionAlterations in DNA methylation span a wide spectrum of health conditions and diseases, with choline being a potential nutritional modulator through its role as a methyl donor. However, these modulatory effects are not unidirectional as they show subtle variations with context-specificity, highlighting the importance of precision in clinical methyl donor interventions. Studies that comprehensively map DNA methylation patterns and aim to establish causality may serve as an important gateway to identify relevant biomarkers, optimize choline-based therapeutic strategies, and confer more precise epigenetic modulation with translational relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.